Acute effects of glucagon-like peptide-1, GLP-19–36 amide, and exenatide on mesenteric blood flow, cardiovascular parameters, and biomarkers in healthy volunteers

Physiological Reports

Volumn 5, Issue 4, 2017, Pages

  Bremholm, Lasse ^a   Andersen, Ulrik B ^a   Hornum, Mads ^a   Hilsted, Linda ^a   Veedfald, Simon ^b   Hartmann, Bolette ^b   Holst, Jens Juul ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Exenatide; glucagon like peptide 1; mesenteric blood flow

Indexed keywords

BIOLOGICAL MARKER; C PEPTIDE; CHORIONIC GONADOTROPIN; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 9 36 AMIDE; GLUCOSE OXIDASE; INSULIN; PANCREAS POLYPEPTIDE; UNCLASSIFIED DRUG; GLUCAGON-LIKE PEPTIDE-1 (9-36)-AMIDE; PEPTIDE; VENOM;

ADULT; ARTICLE; BLOOD FLOW; BLOOD PRESSURE; CARDIOVASCULAR PARAMETERS; CELIAC ARTERY; CHEMILUMINESCENCE IMMUNOASSAY; CONTROLLED STUDY; DOPPLER FLOWMETRY; DOUBLE BLIND PROCEDURE; FEMALE; HEART OUTPUT; HEART RATE; HEART STROKE VOLUME; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY ARTERY; MALE; MESENTERIC ARTERY; MESENTERY BLOOD FLOW; NORMAL HUMAN; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; RESISTIVE INDEX; YOUNG ADULT; ANALOGS AND DERIVATIVES; BLOOD; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; HEMODYNAMICS; KIDNEY CIRCULATION; SPLANCHNIC BLOOD FLOW; TREATMENT OUTCOME;

ADULT; BIOMARKERS; BLOOD GLUCOSE; BLOOD PRESSURE; CARDIAC OUTPUT; DOUBLE-BLIND METHOD; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HEALTHY VOLUNTEERS; HEART RATE; HEMODYNAMICS; HUMANS; MALE; PANCREATIC POLYPEPTIDE; PEPTIDES; RENAL CIRCULATION; SPLANCHNIC CIRCULATION; TREATMENT OUTCOME; VENOMS; YOUNG ADULT;

EID: 85014126783     PISSN: None     EISSN: 2051817X     Source Type: Journal    
DOI: 10.14814/phy2.13102     Document Type: Article

References (47)

1. Asmar, A., L. Simonsen, M. Asmar, S. Madsbad, J. J. Holst, E. Frandsen, et al. 2015. Renal extraction and acute effects of glucagon-like peptide-1 on central and renal hemodynamics in healthy men. Am. J. Physiol. Endocrinol. Metab. 308:E641–E649.
2. Ban, K., M. H. Noyan-Ashraf, J. Hoefer, S.-S. Bolz, D. J. Drucker, and M. Husain. 2008. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 117:2340–2350.
3. Bremholm, L., M. Hornum, B. M. Henriksen, S. Larsen, and J. J. Holst. 2009. Glucagon-like peptide-2 increases mesenteric blood flow in humans. Scand. J. Gastroenterol. 44:314–319.
4. Bremholm, L., M. Hornum, U. B. Andersen, B. Hartmann, J. J. Holst, and P. B. Jeppesen. 2011. The effect of glucagon-like peptide-2 on mesenteric blood flow and cardiac parameters in end-jejunostomy short bowel patients. Regul. Pept. 168:32–38.
5. Buhl, T., L. Thim, H. Kofod, C. Orskov, H. Harling, and J. J. Holst. 1988. Naturally occurring products of proglucagon 111-160 in the porcine and human small intestine. J. Biol. Chem. 263:8621–8624.
6. Deacon, C. F., A. H. Johnsen, and J. J. Holst. 1995. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J. Clin. Endocrinol. Metab. 80:952–957.
7. Deacon, C. F., A. Plamboeck, S. Møller, and J. J. Holst. 2002. GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion. Am. J. Physiol. Endocrinol. Metab. 282:E873–E879.
8. Dirksen, C., N. B. Jørgensen, K. N. Bojsen-Møller, U. Kielgast, S. H. Jacobsen, T. R. Clausen, et al. 2013. Gut hormones, early dumping and resting energy expenditure in patients with good and poor weight loss response after Roux-en-Y gastric bypass. Int. J. Obes. (Lond) 37:1452–1459.
9. Drucker, D. J., P. Erlich, S. L. Asa, and P. L. Brubaker. 1996. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc. Natl. Acad. Sci. U S A 93:7911–7916.
10. Flint, A., A. Raben, A. Astrup, and J. J. Holst. 1998. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J. Clin. Invest. 101:515–520.
11. Gutzwiller, J.-P., S. Tschopp, A. Bock, C. E. Zehnder, A. R. Huber, M. Kreyenbuehl, et al. 2004. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J. Clin. Endocrinol. Metab. 89:3055–3061.
12. Gutzwiller, J.-P., P. Hruz, A. R. Huber, C. Hamel, C. Zehnder, J. Drewe, et al. 2006. Glucagon-like peptide-1 is involved in sodium and water homeostasis in humans. Digestion 73:142–150.
13. Hansen, L., and J. J. Holst. 2002. The effects of duodenal peptides on glucagon-like peptide-1 secretion from the ileum. A duodeno–ileal loop? Regul. Pept. 110:39–45.
14. Hartmann, B., A. H. Johnsen, C. Orskov, K. Adelhorst, L. Thim, and J. J. Holst. 2000a. Structure, measurement, and secretion of human glucagon-like peptide-2. Peptides 21:73–80.
15. Hartmann, B., J. Thulesen, H. Kissow, S. Thulesen, C. Orskov, C. Ropke, et al. 2000b. Dipeptidyl peptidase IV inhibition enhances the intestinotrophic effect of glucagon-like peptide-2 in rats and mice. Endocrinology 141:4013–4020.
16. Holst, J. J. 2007. The physiology of glucagon-like peptide 1. Physiol. Rev. 87:1409–1439.
17. Holst, J. J., C. F. Deacon, T. Vilsbøll, T. Krarup, and S. Madsbad. 2008. Glucagon-like peptide-1, glucose homeostasis and diabetes. Trends Mol. Med. 14:161–168.
18. Jacobsen, S. H., S. C. Olesen, C. Dirksen, N. B. Jørgensen, K. N. Bojsen-Møller, U. Kielgast, et al. 2012. Changes in gastrointestinal hormone responses, insulin sensitivity, and beta-cell function within 2 weeks after gastric bypass in non-diabetic subjects. Obes. Surg. 22:1084–1096.
19. Jensen, E. P., S. S. Poulsen, H. Kissow, N.-H. Holstein-Rathlou, C. F. Deacon, B. L. Jensen, et al. 2015. Activation of GLP-1 receptors on vascular smooth muscle cells reduces the autoregulatory response in afferent arterioles and increases renal blood flow. Am. J. Physiol. Renal. Physiol. 308:F867–F877.
20. Kielgast, U., J. J. Holst, and S. Madsbad. 2011. Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual β-cell function. Diabetes 60:1599–1607.
21. Klonoff, D. C., J. B. Buse, L. L. Nielsen, X. Guan, C. L. Bowlus, J. H. Holcombe, et al. 2008. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr. Med. Res. Opin. 24:275–286.
22. Knudsen, L. B., and L. Pridal. 1996. Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. Eur. J. Pharmacol. 318:429–435.
23. Korner, J., M. Bessler, L. J. Cirilo, I. M. Conwell, A. Daud, N. L. Restuccia, et al. 2005. Effects of Roux-en-Y gastric bypass surgery on fasting and postprandial concentrations of plasma ghrelin, peptide YY, and insulin. J. Clin. Endocrinol. Metab. 90:359–365.
24. Meier, J. J., A. Gethmann, M. A. Nauck, O. Götze, F. Schmitz, C. F. Deacon, et al. 2006. The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans. Am. J. Physiol. Endocrinol. Metab. 290:E1118–E1123.
25. Orskov, C., J. J. Holst, S. Knuhtsen, F. G. Baldissera, S. S. Poulsen, and O. V. Nielsen. 1986. Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. Endocrinology 119:1467–1475.
26. Orskov, C., L. Rabenhøj, A. Wettergren, H. Kofod, and J. J. Holst. 1994. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 43:535–539.
27. Pi-Sunyer, X., S. C. A. L. E. Obesity, and Prediabetes Investigators. 2015. Liraglutide in Weight Management. N. Engl. J. Med. 373:1781–1782.
28. Pyke, C., and L. B. Knudsen. 2013. The glucagon-like peptide-1 receptor–or not? Endocrinology 154:4–8.
29. Pyke, C., R. S. Heller, R. K. Kirk, C. Ørskov, S. Reedtz-Runge, P. Kaastrup, et al. 2014. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology 155:1280–1290.
30. Richter, G., O. Feddersen, U. Wagner, P. Barth, R. Göke, and B. Göke. 1993. GLP-1 stimulates secretion of macromolecules from airways and relaxes pulmonary artery. Am. J. Physiol. 265:L374–L381.
31. Schwartz, T. W., J. J. Holst, J. Fahrenkrug, S. L. Jensen, O. V. Nielsen, J. F. Rehfeld, et al. 1978. Vagal, cholinergic regulation of pancreatic polypeptide secretion. J. Clin. Invest. 61:781–789.
32. Simonsen, L., S. Pilgaard, C. Orskov, M. M. Rosenkilde, B. Hartmann, J. J. Holst, et al. 2007. Exendin-4, but not dipeptidyl peptidase IV inhibition, increases small intestinal mass in GK rats. Am. J. Physiol. Gastrointest. Liver Physiol. 293:G288–G295.
33. Sivertsen, J., J. Rosenmeier, J. J. Holst, and T. Vilsbøll. 2012. The effect of glucagon-like peptide 1 on cardiovascular risk. Nat. Rev. Cardiol. 9:209–222.
34. Sjøberg, K. A., J. J. Holst, S. Rattigan, E. A. Richter, and B. Kiens. 2014. GLP-1 increases microvascular recruitment but not glucose uptake in human and rat skeletal muscle. Am. J. Physiol. Endocrinol. Metab. 306:E355–E362.
35. Skov, J., A. Dejgaard, J. Frøkiær, J. J. Holst, T. Jonassen, S. Rittig, et al. 2013. Glucagon-like peptide-1 (GLP-1): effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men. J. Clin. Endocrinol. Metab. 98:E664–E671.
36. Sun, F., S. Wu, S. Guo, K. Yu, Z. Yang, L. Li, et al. 2015. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Res. Clin. Pract. 110:26–37.
37. Tate, M., A. Chong, E. Robinson, B. D. Green, and D. J. Grieve. 2015. Selective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetes. Br. J. Pharmacol. 172:721–736.
38. Thorens, B., A. Porret, L. Bühler, S. P. Deng, P. Morel, and C. Widmann. 1993. Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes 42:1678–1682.
39. Tolessa, T., M. Gutniak, J. J. Holst, S. Efendic, and P. M. Hellström. 1998. Glucagon-like peptide-1 retards gastric emptying and small bowel transit in the rat: effect mediated through central or enteric nervous mechanisms. Dig. Dis. Sci. 43:2284–2290.
40. Trahair, L. G., M. Horowitz, T. Hausken, C. Feinle-Bisset, C. K. Rayner, and K. L. Jones. 2014. Effects of exogenous glucagon-like peptide-1 on the blood pressure, heart rate, mesenteric blood flow, and glycemic responses to intraduodenal glucose in healthy older subjects. J. Clin. Endocrinol. Metab. 99:E2628–E2634.
41. Trahair, L. G., M. Horowitz, J. E. Stevens, C. Feinle-Bisset, S. Standfield, D. Piscitelli, et al. 2015. Effects of exogenous glucagon-like peptide-1 on blood pressure, heart rate, gastric emptying, mesenteric blood flow and glycaemic responses to oral glucose in older individuals with normal glucose tolerance or type 2 diabetes. Diabetologia 58:1769–1778.
42. Ussher, J. R., and D. J. Drucker. 2014. Cardiovascular actions of incretin-based therapies. Circ. Res. 114:1788–1803.
43. Vilsbøll, T., M. B. Toft-Nielsen, T. Krarup, S. Madsbad, B. Dinesen, and J. J. Holst. 2000. Evaluation of beta-cell secretory capacity using glucagon-like peptide 1. Diabetes Care 23:807–812.
44. Wettergren, A., B. Schjoldager, P. E. Mortensen, J. Myhre, J. Christiansen, and J. J. Holst. 1993. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig. Dis. Sci. 38:665–673.
45. Wettergren, A., M. Wøjdemann, and J. J. Holst. 1998a. The inhibitory effect of glucagon-like peptide-1 (7-36)amide on antral motility is antagonized by its N-terminally truncated primary metabolite GLP-1 (9-36)amide. Peptides 19:877–882.
46. Wettergren, A., M. Wøjdemann, and J. J. Holst. 1998b. Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow. Am J Physiol. 275:G984–92.
47. Wewer Albrechtsen, N. J., M. J. Bak, B. Hartmann, L. W. Christensen, R. E. Kuhre, C. F. Deacon, et al. 2015. Stability of glucagon-like peptide 1 and glucagon in human plasma. Endocr Connect. 4:50–57.